1. Immunogenicity analysis based on VP1 and VP2 proteins of bovine enterovirus.
- Author
-
Peng Y, Luo Y, Pan L, Hou Y, Qin L, Lan L, Ouyang K, Chen Y, Wei Z, Qin Y, and Huang W
- Subjects
- Animals, Mice, Cattle, Mice, Inbred ICR, Female, Immunization, Capsid Proteins immunology, Capsid Proteins genetics, Enterovirus, Bovine genetics, Enterovirus, Bovine immunology, Antibodies, Viral immunology, Antibodies, Viral blood, Antibodies, Neutralizing immunology, Antibodies, Neutralizing blood, Enterovirus Infections virology, Enterovirus Infections veterinary, Enterovirus Infections immunology, Enterovirus Infections prevention & control, Viral Vaccines immunology, Viral Vaccines administration & dosage, Viral Vaccines genetics, Cattle Diseases virology, Cattle Diseases immunology, Cattle Diseases prevention & control
- Abstract
Bovine enterovirus (BEV) infection manifests as a spectrum of clinical signs affecting the respiratory, gastrointestinal, and reproductive systems in cattle. Outbreaks of this disease results in large economic losses to the bovine industry worldwide. Currently there are no efficacious vaccines and medicines to prevent BEV infection. In the present study, reverse transcription-polymerase chain reaction was used to amplify the VP1 and VP2 genes of BEV, enabling the synthesis of a chimeric recombinant protein which contained partial sequences from both proteins. Subsequently, the emulsified purified proteins with Freund's adjuvant were used for triple-fold immunization of 4-week-old Institute of Cancer Research (ICR) mice. The mice were subsequently subjected to a challenge assay which elicited an immune response that was characterized by elevated titers of BEV-specific neutralizing antibodies. Notably, the results showed that the purification of pET32a-VP1 and pET32a-VP2 proteins markedly curtailed virus excretion and mitigated the histopathological damage usually associated with BEV infections. These were observed in the small intestines, kidneys and brain in infected animals. It also alleviated clinical symptoms such as hypothermia and weight loss. In summary, this study offers a theoretical and practical basis for BEV vaccine development., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF